Myborte Adverse Reactions

Common Adverse Effects: Adverse effects reported in 20% or more of patients with previously untreated multiple myeloma receiving bortezomib plus melphalan and prednisone (VMP) (in order of descending frequency) include thrombocytopenia, neutropenia, nausea, peripheral neuropathy, diarrhea, anemia, constipation, neuralgia, leukopenia, vomiting, pyrexia, fatigue, lymphopenia, anorexia, asthenia, cough, peripheral edema, and insomnia. Serious (grade 3 or higher) adverse effects reported in 5% or more of patients receiving VMP include neutropenia, thrombocytopenia, leukopenia, anemia, lymphopenia, peripheral neuropathy, neuralgia, diarrhea, fatigue, asthenia, hypokalemia, and pneumonia.
Adverse effects reported in 20% or more of patients with relapsed multiple myeloma receiving bortezomib include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, paresthesia and dysesthesia, anemia, headache, cough, and dyspnea. Serious (grade 3 or higher) adverse effects reported in 5% or more of patients receiving bortezomib include thrombocytopenia, asthenic condition, neutropenia, anemia, diarrhea, peripheral neuropathy, and dyspnea.
Adverse effects reported in 20% or more of patients with mantle cell lymphoma receiving bortezomib include asthenic conditions, peripheral neuropathy, constipation, diarrhea, nausea, decreased appetite, rash, dyspnea, dizziness (excluding vertigo), and insomnia. Serious (grade 3 or higher) adverse effects reported in 5% or more of patients receiving bortezomib include asthenic conditions, peripheral neuropathy, thrombocytopenia, diarrhea, dyspnea; abdominal pain, pneumonia, and dehydration.